JPMorgan Chase & Co. Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00
Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its target price cut by JPMorgan Chase & Co. from $11.00 to $9.00 in a research report sent to investors on Monday morning, Marketbeat.com reports. They currently have an overweight rating on the stock. ALLO has been the subject of a number of other research reports. Oppenheimer reaffirmed […]